{"schema_version":"secwatch.filing_event.v1","accession":"0001567892-24-000045","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2024-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.822959+00:00","generated_at":"2026-05-29T07:15:24.845426+00:00","sec_items":["2.01","2.04","1.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mallinckrodt completes Therakos sale, uses $887.6M net proceeds to cut net debt >60%","bullets":["Closed Therakos divestiture for $925M base; net cash $887.6M after working capital adjustments.","Mandatory debt prepayment on Dec 6: ~$474.1M term loans ($36.4M makewhole) and ~$301.4M notes ($27.3M makewhole).","Total principal reduction ~$775.5M; net debt expected to fall more than 60%.","Board adopted Second A&R Transaction Incentive Plan; bonus pool capped at 3% of transaction proceeds.","PSU award agreements amended to convert to time-vested upon a Qualifying Significant Event."],"urls":{"canonical":"https://secwatch.observer/filing/0001567892-24-000045","json":"https://secwatch.observer/filing/0001567892-24-000045.json","markdown":"https://secwatch.observer/filing/0001567892-24-000045.md","text":"https://secwatch.observer/filing/0001567892-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000045/0001567892-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000045/mnk-20241129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T07:15:24.845426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6721712764c8961b39d215f752c15c80cba7970e","claim":"Keenova Therapeutics plc completed a disposition involving CVC Capital Partners Fund IX (affiliates Solaris Bidco Limited, Solaris IPCo Limited, Solaris US BidCo, LLC) for $925.0 million (closed 2024-11-29).","evidence_excerpt":"to the conditions set forth in the Agreement, Purchasers agreed to acquire the Therakos Business from the Company (the “Therakos Transaction”) for a base purchase price of $925.0 million, subject to customary adjustments. On November 29, 2024, the Company completed the sale of the Therakos Business for total cash consideration of $887.6 million, which amount is","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000045/0001567892-24-000045-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"CVC Capital Partners Fund IX (affiliates Solaris Bidco Limited, Solaris IPCo Limited, Solaris US BidCo, LLC)"},{"label":"Consideration","value":"$925.0 million"},{"label":"Closing","value":"2024-11-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}